ArticleJournal of research in pharmacy practice
Evaluation of Synergistic Effect of Colistin with Levofloxacin and Meropenem against Multidrug-resistant
Article in Journal of research in pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Many antibiotics currently in use show limited effectiveness against Methods: Utilizing the broth microdilution approach, the minimum inhibitory concentration (MIC) of levofloxacin, colistin, and meropenem versus isolates of MDR-AB obtained from hospitalized individuals with nosocomial infections caused by this pathogen was ascertained. The checkerboard approach was also used to determine the antibiotics' simultaneous effects on the pathogen. Findings: Twenty isolates underwent testing. Every isolate was meropenem-resistant. Conversely, all 20 isolates showed sensitivity to colistin, with a MIC range of 0.031-2 µg/mL. The synergy test revealed that no instances of antagonistic interactions existed between meropenem and colistin in 60% of isolates, indicating partial synergy (additive impact). However, only 40% of isolates demonstrated partial synergism with no instances of antagonistic behavior when colistin and levofloxacin were administered together. Conclusion: Levofloxacin and meropenem exhibit respectable synergistic effects when combined with colistin; as a result, these combinations may be clinically assessed for MDR-AB infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.